Chinese Hamster Ovary (i.e., Cho) Patents (Class 435/358)
Expressing recombinant tpa (Class 435/359)
Expressing recombinant hormone or growth factor (Class 435/360)
Expressing recombinant receptor (Class 435/361)
Expressing recombinant antigen (Class 435/362)
  • APO-2 LIGAND/TRAIL VARIANTS AND USES THEREOF
    Publication number: 20130165383
    Abstract: The disclosure provides Apo-2 ligand variant polypeptides. Methods of making and chemically modifying Apo-2 ligand variant polypeptides are also provided. In addition, formulations of Apo-2 ligand variant polypeptides are provided. In addition, therapeutic methods for using Apo-2 ligand variant polypeptides are provided.
    Type: Application
    Filed: April 6, 2012
    Publication date: June 27, 2013
    Applicant: Genentech, Inc.
    Inventors: Robert F. Kelley, Sarah Hymowitz
  • MUTANT G-CSF FUSION PROTEIN, AND PREPARATION AND USE THEREOF
    Publication number: 20130164251
    Abstract: The present invention relates to a mutant G-CSF fusion protein. The mutant G-CSF fusion protein is a fusion protein having the activity of stimulating the proliferation of neutrophilic granulocytes, and having a basic structure of G-CSF/carrier protein or carrier protein/G-CSF; wherein the G-CSF moiety comprises multipoint substitutions thus resulting in changes in biological activity and binding affinity. Compared with existing products, the mutant G-CSF fusion protein in the present invention has longer half-life and higher biological activity. Administration of the pharmaceutical preparation containing this mutant G-CSF fusion protein could be used in the treating neutropenia.
    Type: Application
    Filed: June 30, 2010
    Publication date: June 27, 2013
    Inventors: Xiaofang Wen, Yiliang Wu, Yefei Wang, Zhiyu Yang, Min Fan, Yujiao Wang, Xiaochun Fang, You Lu
  • CELL-PENETRATING PEPTIDES AND USES THEREOF
    Publication number: 20130164219
    Abstract: The present invention relates to the identification and functional characterization of human cell-penetrating peptides (CPPs) and their use; in particular as transfection vehicles.
    Type: Application
    Filed: December 12, 2012
    Publication date: June 27, 2013
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventor: Hoffmann-La Roche Inc.
  • METHODS AND COMPOSITIONS FOR INACTIVATING GLUTAMINE SYNTHETASE GENE EXPRESSION
    Publication number: 20130164785
    Abstract: Disclosed herein are methods and compositions for inactivating a glutamine synthetase (GS) gene, using fusion proteins comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins.
    Type: Application
    Filed: September 6, 2012
    Publication date: June 27, 2013
    Inventors: Pei-Qi Liu, Jeffrey C. Miller
  • FUCOSYLATION-DEFICIENT CELLS
    Publication number: 20130164786
    Abstract: An isolated nucleic acid encoding an FX protein having a serine at position 79, a lysine at position 90, a leucine at position 136, an arginine at position 211, a serine at position 289, and a combination thereof is provided. Cells having a gene encoding a modified FX protein are provided, wherein the cells exhibit a reduced ability to fucosylate a glycoprotein at a first temperature, but exhibit the ability to fucosylate the glycoprotein at a second temperature. Methods and compositions for making glycoproteins with reduced fucosylation are provided.
    Type: Application
    Filed: February 28, 2013
    Publication date: June 27, 2013
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventor: REGENERON PHARMACEUTICALS, INC.
  • GENE AMPLIFICATION AND TRANSFECTION METHODS AND REAGENTS RELATED THERETO
    Publication number: 20130164851
    Abstract: Provided herein are methods and compositions for generating a cell line capable of producing a biological product, using a gene amplification based system. Methods and compositions are provided to inhibit endogenous selectable amplifiable marker genes using RNA interference and prevent the selection of false positives during generation of a custom cell line. Such methods improve efficiency of cell line development and do not require the use of specialized substrates or cells lacking the endogenous selectable amplifiable marker gene to negate the effect of endogenously expressed levels of the selectable amplifiable marker gene in cells.
    Type: Application
    Filed: March 25, 2011
    Publication date: June 27, 2013
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Anthony Rossomando, Gregory P. Thill, Stuart Pollard
  • BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF (1R,2R)-2-(3,4-DIMETHOXYPHENETHOXY)CYCLOHEXAMINE
    Publication number: 20130164794
    Abstract: The disclosure provides transaminase polypeptides capable of converting the substrate, 2-(3,4-dimethoxyphenethoxy)cyclohexanone to the trans diastereomer product (1R,2R)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine in at least a 2:1 diastereomeric ratio relative to the cis diastereomer (1R,2S)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine. The disclosure also provides polynucleotides, vectors, host cells, and methods of making and using the transaminase polypeptides in processes for preparing (1R,2R)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine and its analogs, which can product compounds can be further used to prepare the aminocyclohexylether compound, (3R)-1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]pyrrolidin-3-ol, which is an ion channel blocker.
    Type: Application
    Filed: August 8, 2011
    Publication date: June 27, 2013
    Applicant: CODEXIS, INC.
    Inventors: John Limanto, Gregory Beutner, Brendan Grau, Jacob Janey, Artis Klapars, Eric Ashley, Hallena R. Strotman, Matthew D. Truppo, Gregory Hughes, Fabien L. Cabirol, Anupam Gohel, Steven J. Collier, Jack Liang, Marissa Mock, Emily Mundorff, Scott Novick, Derek Smith
  • METHODS & COMPOSITIONS FOR IMPROVING PROTEIN PRODUCTION
    Publication number: 20130157356
    Abstract: The invention relates to compositions, and uses thereof, which are beneficial for eukaryotic cells in culture, and methods for their use in promoting cell growth, viability and recombinant protein expression. The methods disclosed in the present application are useful, for example, for improving cell viability and in accelerating the rate of cell growth of cells grown in culture. In one aspect, the supplements of the invention are useful for improving or enhancing the yield of the recombinant proteins from the cell cultures.
    Type: Application
    Filed: January 24, 2011
    Publication date: June 20, 2013
    Applicant: VENTRIA BIOSCIENCE
    Inventors: Michael E. Barnett, Matthew S. Croughan
  • HCV NS5B PROTEASE MUTANTS
    Publication number: 20130157258
    Abstract: The invention provides polypeptides comprising an amino acid sequence comprising at least one variation from wild-type HCV NS5B polymerase, the at least one variation selected from the group consisting of cysteine, isoleucine, valine, or proline at amino acid position 419; alanine, valine, or asparagine at amino acid position 482; valine, isoleucine, threonine, or serine at amino acid position 486; and isoleucine at amino acid position 494, as the amino acid positions are defined in SEQ ID NO: 1, and having Hepatitis C Virus (HCV) NS5B polymerase activity. Polynucleotides encoding the polypeptide, antibodies, host cells, compositions, and methods for detecting an HCV NS5B polymerase having resistance to a polymerase inhibitor also are provided.
    Type: Application
    Filed: June 15, 2011
    Publication date: June 20, 2013
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Douglas J. Bartels, Min Jiang, Tara Lynn Kieffer, Olivier Nicolas
  • NOVEL INTERGENIC ELEMENTS FOR ENHANCING GENE EXPRESSION
    Publication number: 20130157312
    Abstract: The present invention relates to nucleic acid fragments and constructs comprising genomic nucleotide sequences, which are present upstream of Rb1 and p15C that are associated with intergenic transcription, for the production of a gene product of interest in a eukaryotic, preferably mammalian, host cell in the presence of a stringent selectable marker. The invention further relates to host cells comprising the nucleic acid constructs, to methods for generating the host cells and to methods for producing a gene product of interest using the host cells.
    Type: Application
    Filed: June 15, 2011
    Publication date: June 20, 2013
    Inventors: Arie Pieter Otte, Michel Siep, John Antonius Verhess, Femke Hoeksema
  • COLORIMETRIC AND FLUORESCENT PROTEINS
    Publication number: 20130157284
    Abstract: The invention relates to intracellular lipid binding proteins that bind retinoids and/or dye ligands and that are modified to transmit or emit light at a variety of different wavelengths.
    Type: Application
    Filed: March 23, 2011
    Publication date: June 20, 2013
    Applicant: Board of Trustees of Michigan State University
    Inventors: Babak Borhan, James Geiger, Wenjing Wang, Chrysoula Vasileiou, Kin Sing Lee, Tetyana Berbasova
  • NUCLEIC ACIDS MOLECULE ENCODING THE POLYPEPTIDE FOR TREATING VIRUS-INDUCED CANCER
    Publication number: 20130143316
    Abstract: The present invention relates to nucleic acid molecules encoding the polypeptides that are capable of killing tumor cells. The molecules comprise a targeting agent covalently attached to a channel-forming moiety. In a preferred embodiment, the channel-forming moiety comprises a colicin and the targeting agent is a reconstructed antibody mimetic derived from monoclone antibody against Epstein-Barr virus gp350/220.
    Type: Application
    Filed: December 7, 2012
    Publication date: June 6, 2013
    Applicant: PHEROMONICIN BIOTECH, LTD.
    Inventor: PHEROMONICIN BIOTECH, LTD.
  • THERAPEUTIC APYRASE CONSTRUCTS, APYRASE AGENTS, AND PRODUCTION METHODS
    Publication number: 20130142775
    Abstract: This invention provides a new class of enhanced apyrases (EN-apyrases) with superior pharmacokinetic, pharmacodynamic, and pharmacochemical properties and which can be purified using simplified procedures. The invention further provides constructs for transforming a cell to produce these EN-apyrases. The EN-apyrase construct comprises sequences encoding a signal sequence, a linker, and a soluble apyrase. Also provided are preparations of apyrases and methods for producing apyrase in culture cells and purification thereof.
    Type: Application
    Filed: January 13, 2011
    Publication date: June 6, 2013
    Applicant: APT THERAPEUTICS, INC.
    Inventors: Ridong Chen, Soon Seog Jeong
  • HIGH EFFICIENCY GENE TRANSFER AND EXPRESSION IN MAMMALIAN CELLS BY AMULTIPLE TRANSFECTION PROCEDURE OF MAR SEQUENCES
    Publication number: 20130143264
    Abstract: The present invention relates to purified and isolated DNA sequences having protein production increasing activity and more specifically to the use of matrix attachment regions (MARs) for increasing protein production activity in a eukaryotic cell. Also disclosed is a method for the identification of said active regions, in particular MAR nucleotide sequences, and the use of these characterized active MAR sequences in a new multiple transfection method.
    Type: Application
    Filed: June 28, 2012
    Publication date: June 6, 2013
    Applicant: SELEXIS SA
    Inventors: Mermod Nicolas, Pierre Alain Girod, Philipp Bucher, Duc-Quang Nguyen, David Calabrese, Damien Saugy, Stefania Puttini
  • Serum-free mammalian cell culture medium, and uses thereof
    Patent number: 8455246
    Abstract: The present invention provides a cell culture medium formulation that supports the in vitro cultivation, particularly in suspension, of mammalian cells, particularly epithelial cells and fibroblast cells, and methods for cultivating mammalian cells in suspension in vitro using these media. The media comprise a basal medium and a polyanionic or polyanionic compound, preferably a polysulfonated or polysulfated compound, and more preferably dextran sulfate. The present invention also provides chemically defined, protein-free eukaryotic cell culture media comprising an iron chelate and zinc, which is capable of supporting the growth (and particularly the high-density growth of mammalian cells) in suspension culture, increasing the level of expression of recombinant protein in cultured cells, and/or increasing virus production in cultured cells.
    Type: Grant
    Filed: May 8, 2009
    Date of Patent: June 4, 2013
    Assignee: Life Technologies Corporation
    Inventors: Stephen Gorfien, Richard Fike, Glenn Godwin, Joyce Dzimian, David A. Epstein, Dale Gruber, Paul Price
  • METHODS OF EVALUATING GENETIC ELEMENTS
    Publication number: 20130137604
    Abstract: The invention relates to compositions for evaluating a genetic element and methods of use.
    Type: Application
    Filed: November 29, 2012
    Publication date: May 30, 2013
    Applicant: Raytheon BBN Technologies Corp.
    Inventor: Raytheon BBN Technologies Corp.
  • Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
    Patent number: 8450470
    Abstract: Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: May 28, 2013
    Assignee: Halozyme, Inc.
    Inventors: Louis H. Bookbinder, Anirbau Kundu, Gregory I. Frost
  • METHOD OF SYNTHESIZING A SUPPRESSOR tRNA, DNA CONSTRUCT AND USE THEREOF FOR PRODUCING A NON-NATURAL AMINO ACID-INCORPORATED PROTEIN
    Publication number: 20130130313
    Abstract: There are provided a DNA construct comprising a suppressor tRNA gene of a non-eukaryote containing no internal promoter functioning in a eukaryotic cell, and a eukaryotic or bacteriophage promoter linked at the 5? end of the tRNA gene, a method for synthesizing a suppressor tRNA by using the DNA construct, and a process for producing protein incorporating a non-natural amino acid by using the same.
    Type: Application
    Filed: April 30, 2012
    Publication date: May 23, 2013
    Applicant: RIKEN
    Inventors: Shigeyuki YOKOYAMA, Kensaku Sakamoto, Nobumasa Hino, Takahito Mukai, Takatsugu Kobayashi
  • METHOD OF PRODUCING RECOMBINANT PROTEINS WITH MANNOSE-TERMINATED N-GLYCANS
    Publication number: 20130129755
    Abstract: We describe a method of expressing a recombinant protein comprising mannose-terminated N-glycans from a host cell, the method comprising: (a) introducing a nucleic acid encoding a recombinant protein into a Chinese Hamster Ovary (CHO) cell comprising a mutation in the GnT 1 gene (GenBank Accession Number AF343963) leading to loss of GnT 1 function; and (c) expressing the recombinant protein from the host cell, in which the expressed recombinant protein comprises a mannose-terminated glycan structure, and in which the method does not include a step of introducing functional GnT-1 into the host cell. The method may be used for producing recombinant glucocerebrosidase with a mannose-terminated glycan structure, suitable for treatment or prevention of Gaucher's Disease.
    Type: Application
    Filed: March 24, 2011
    Publication date: May 23, 2013
    Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventor: Zhiwei Song
  • Kit Comprising Serum Replacement and Labile Factors
    Publication number: 20130130373
    Abstract: The present disclosure relates, in general to a kit comprising a serum replacement and one or more labile factors, such as growth factors, packaged separately in the kit. It is contemplated that the kit provides advantages to improve cell growth in culture compared to cells cultured not using the kit described herein.
    Type: Application
    Filed: November 9, 2012
    Publication date: May 23, 2013
    Applicant: ESSENTIAL PHARMACEUTICALS, LLC
    Inventor: Essential Pharmaceuticals, LLC
  • METHOD FOR DETECTING INTERACTIONS BETWEEN TWO AND MORE BIOLOGICAL MACROMOLECULES
    Publication number: 20130130273
    Abstract: Disclosed is a novel method for detecting interactions of biomolecules. More particularly, the disclosed method includes (a) preparing a cell comprising (i) a first construct comprising a bait, a first labeling material and a translocation module; and (ii) a second construct comprising a prey and a second labeling material; (b) detecting the distribution of the first construct and the second construct in the cell. the present invention provides a method capable of detecting bindings and interactions occurring in a living cell in real time, and a method for screening a material that alters the binding and the interaction. The method of the present invention overcomes the disadvantages including inaccuracy and complexity of existing biomaterial interaction detection techniques. By labeling both constructs to promote accuracy, the present invention provides a novel real-time, antibody-free analysis.
    Type: Application
    Filed: January 3, 2013
    Publication date: May 23, 2013
    Applicant: Korea Basic Science Institute
    Inventor: Korea Basic Science Institute
  • TARGETING SIGNAL FOR INTEGRATING PROTEINS, PEPTIDES AND BIOLOGICAL MOLECULES INTO BACTERIAL MICROCOMPARTMENTS
    Publication number: 20130133102
    Abstract: A conserved region of sequence in bacterial microcompartment (BMC) enzymes and proteins was identified. Peptide sequences derived from this conserved region of native BMC proteins and enzymes appear to target the hexameric facets of BMC shell proteins. These peptides were predicted to share general properties of a predicted alpha helical conformation, flanked by poorly conserved segment(s) of primary structure); for each type of encapsulated protein, and for each functionally distinct BMC. These peptides can be used as targeting signals for integrating biomolecules and molecules into bacterial microcompartments or for attaching molecules or biomolecules to native or non-native bacterial microcompartment shell proteins.
    Type: Application
    Filed: August 1, 2012
    Publication date: May 23, 2013
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Cheryl A. Kerfeld, James N. Kinney
  • ENDORIBONUCLEASE COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20130130248
    Abstract: The present disclosure provides variant Csy4 endoribonucleases, nucleic acids encoding the variant Csy4 endoribonucleases, and host cells genetically modified with the nucleic acids. The variant Csy4 endoribonucleases find use in a variety of applications, which are also provided. The present disclosure also provides methods of detecting a specific sequence in a target polyribonucleotide; and methods of regulating production of a target RNA in a eukaryotic cell.
    Type: Application
    Filed: November 7, 2012
    Publication date: May 23, 2013
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
  • ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20130129693
    Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of reversing anticoagulation, stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Application
    Filed: August 21, 2012
    Publication date: May 23, 2013
    Inventors: Uma Sinha, Genmin Lu, Pamela B. Conley
  • Immunosuppressive polypeptides and nucleic acids
    Patent number: 8445230
    Abstract: The invention provides immunosuppressive polypeptides and nucleic acids encoding such polypeptides. In one aspect, the invention provides mutant CTLA-4 polypeptides and nucleic acids encoding mutant CTLA-4 polypeptides. Compositions and methods for utilizing such polypeptides and nucleic acids are also provided.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: May 21, 2013
    Assignee: Perseid Therapeutics LLC
    Inventors: Erik E Karrer, Madan M. Paidhungat, Steven H Bass, Margaret Neighbors, Juha Punnonen, Steven J. Chapin
  • SYNTHETIC GAGPOL GENES AND THEIR USES
    Publication number: 20130122585
    Abstract: The present invention relates to synthetic gag and gagpol genes optimized for high level expression via codon optimization and the uses thereof for the efficient generation of vector particles. The invention further relates to the generation of packaging cells and vaccines based on the synthetic gag and gagpol genes.
    Type: Application
    Filed: September 14, 2012
    Publication date: May 16, 2013
    Applicant: GENEART AG
    Inventors: Ralf WAGNER, Marcus Graf, Ludwig Deml, Kurt Bieler
  • ENHANCED PHYTASE VARIANTS
    Publication number: 20130122567
    Abstract: The present invention provides the field of enhancing proteins and in particular to that of proteins enhanced by molecular change. It provides a variant of a phytase that is termed enhanced in that is has better thermostability and/or activity than the original phytase. The invention also provides a nucleic acid coding for said variant, a cassette or an expression vector containing said variant, a host cell expressing said variant, a composition comprising said variant and uses thereof, principally in the preparation of food additives and animal feed.
    Type: Application
    Filed: July 1, 2010
    Publication date: May 16, 2013
    Applicant: BIOMETHODES
    Inventors: Stephane Blesa, Helene Chautard, Marc Delcourt, Laurent Mesta, Bruno Winter
  • Process for the culturing of cells
    Patent number: 8440458
    Abstract: The invention relates to a process for the culturing of cells, preferably E1-immortalized HER cells, more preferably PER.C6 cells in a reactor in suspension in a cell culture medium, wherein the cells produce a biological substance, preferably an antibody, wherein at least one cell culture medium component is fed to the cell culture and wherein the cell culture comprising the cells, the biological substance and cell culture medium is circulated over a separation system and wherein the separation system separates the biological substance from substances having a lower molecular weight than the biological substance and wherein the biological substance is retained in or fed back into the reactor. Preferably part of the substances of lower molecular weight is continuously removed from the cell culture.
    Type: Grant
    Filed: February 15, 2012
    Date of Patent: May 14, 2013
    Assignee: DSM IP Assets B.V.
    Inventors: Gerben Meile Zijlstra, Robert Patrick Hoff, Jacob Schilder
  • EPITOPE TAG FOR AFFINITY-BASED APPLICATIONS
    Publication number: 20130115635
    Abstract: Described is an epitope tag useful in affinity-based applications. The invention further includes fusion proteins, methods for preparing fusion proteins, nucleic acid molecules encoding these fusion proteins and recombinant host cells that contain these nucleic acid molecules. The invention also relates to nanobodies and other affinity ligands specifically recognizing the epitope tag, and uses thereof in affinity-based applications.
    Type: Application
    Filed: May 25, 2011
    Publication date: May 9, 2013
    Inventors: Els Pardon, Jan Steyaert, Lode Wyns
  • TMEM195 ENCODES FOR TETRAHYDROBIOPTERIN-DEPENDENT ALKYLGLYCEROL MONOOXYGENASE ACTIVITY
    Publication number: 20130116304
    Abstract: The present invention relates to the provision of a pharmaceutical composition comprising a nucleic acid molecule encoding a alkylglycerol monooxygenase (TMEM195; glyceryl ether monooxygenase; EC 1.14.16.5). The present invention also provides for a method for producing said alkylglycerol monooxygenase (TMEM195; glyceryl ether monooxygenase; EC 1.14.16.5) polypeptides encoded by said polynucleotides. Moreover, the use of such polypeptides as well as of antagonists/inhibitors of such polypeptides in a medical setting (e.g. in from of a pharmaceutical composition) and methods for assessing the activity of a candidate molecule suspected of being an antagonist/inhibitor or agonist/activator in order to identify potential antagonists/inhibitors or agonists/activators of the polypeptide are also provided in the present invention.
    Type: Application
    Filed: April 18, 2011
    Publication date: May 9, 2013
    Inventors: Ernst R. Werner, Katrin Watschinger
  • ISOLATED LUCIFERASES AND THE USE THEREOF
    Publication number: 20130115641
    Abstract: The invention relates to the nucleotide and amino acid sequences, and to the activity and use, of the luciferases LuAL, Lu164, Lu16, Lu39, Lu45, Lu52 and Lu22.
    Type: Application
    Filed: July 18, 2012
    Publication date: May 9, 2013
    Applicant: Bayer Intellectual Property GmbH
    Inventors: Stefan GOLZ, Bernd Kalthof, Svetlana Markova, Ludmila Frank, Eugene Vysotski
  • ENONE REDUCTASES
    Publication number: 20130115663
    Abstract: The disclosure relates to engineered enone reductase polypeptides having improved properties, polynucleotides encoding the engineered polypeptides, related vectors, host cells, and methods for making the engineered enone reductase polypeptides. The disclosure also provides methods of using the engineered enone reductase polypeptides for chemical transformations.
    Type: Application
    Filed: October 23, 2012
    Publication date: May 9, 2013
    Applicant: CODEXIS, INC.
    Inventor: Codexis, Inc.
  • METHOD FOR THE GENERATION OF COMPACT TALE-NUCLEASES AND USES THEREOF
    Publication number: 20130117869
    Abstract: The present invention relates to a method for the generation of compact Transcription Activator-Like Effector Nucleases (TALENs) that can efficiently target and process double-stranded DNA. More specifically, the present invention concerns a method for the creation of TALENs that consist of a single TALE DNA binding domain fused to at least one catalytic domain such that the active entity is composed of a single polypeptide chain for simple and efficient vectorization and does not require dimerization to target a specific single double-stranded DNA target sequence of interest and process DNA nearby said DNA target sequence. The present invention also relates to compact TALENs, vectors, compositions and kits used to implement the method.
    Type: Application
    Filed: April 5, 2012
    Publication date: May 9, 2013
    Applicant: Cellectis S.A.
    Inventors: PHILIPPE DUCHATEAU, Julien Valton, Claudia Bertonati, Jean-Charles Epinat, George H. Silva, Alexandre Juillerat
  • Novel Hemopoietin Receptor Protein, NR10
    Publication number: 20130115620
    Abstract: The inventors succeeded in isolating a novel hemopoietin receptor gene (NR10) using a sequence predicted from the extracted motif conserved in the amino acid sequences of known hemopoietin receptors. It was expected that two forms of NR10 exists, a transmembrane type and soluble form. Expression of the former type was detected in tissues containing hematopoietic cells. Thus, NR10 is a novel hemopoietin receptor molecule implicated in the regulation of the immune system and hematopoiesis in vivo. These novel receptors are useful in screening for novel hematopoietic factors capable of functionally binding to the receptor, or developing medicines to treat diseases related with the immune system or hematopoietic system.
    Type: Application
    Filed: December 19, 2012
    Publication date: May 9, 2013
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventor: CHUGAI SEIYAKU KABUSHIKI KAISHA
  • TELOMERASE ACTIVITY INHIBITING PEPTIDE AND MANUFACTURING METHOD AND APPLICATION THEREOF
    Publication number: 20130108654
    Abstract: The present invention provides a telomerase activity inhibiting polypeptide. The expression of the polypeptide in tumor cells can inhibit significantly tumor cell telomerase activity, tumor cell growth, and lead to the death of such cells. The present invention further provides a preparation method for the polypeptide and an application thereof in targeted treatments of tumors.
    Type: Application
    Filed: July 4, 2011
    Publication date: May 2, 2013
    Applicant: SHANGHAI INSTITUTES FOR BIOLOGICAL SCIENCES, CAS
    Inventors: Mujun Zhao, Jian Feng, Guoyuan Chen, Jing Zhao, Guangming Chen, Liang Da, Zaiping Li
  • NOVEL HERBICIDE RESISTANCE GENE
    Publication number: 20130109075
    Abstract: The subject invention provides novel polynucleotides and polypeptides encoding a methyltransferase. The subject invention provides novel plants that express the methyltransferase disclosed herein and are resistant to auxin-based herbicides. The subject invention also provides transgenic plants have been transformed with one or more other herbicide resistance genes such that the plants are resistant to the application of auxin-based herbicides and one or more other herbicides.
    Type: Application
    Filed: December 19, 2012
    Publication date: May 2, 2013
    Applicant: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventor: University of Tennessee Research Foundation
  • APO-2 LIGAND VARIANTS AND USES THEREOF
    Publication number: 20130108578
    Abstract: The disclosure provides Apo-2 ligand variant polypeptides. Methods of making and chemically modifying Apo-2 ligand variant polypeptides are also provided. In addition, formulations of Apo-2 ligand variant polypeptides are provided.
    Type: Application
    Filed: May 17, 2012
    Publication date: May 2, 2013
    Applicant: Genentech, Inc.
    Inventors: Robert F. Kelley, Stephanie Ho Lindstrom
  • Extended Soluble PH20 Polypeptides and uses thereof
    Publication number: 20130101577
    Abstract: Soluble PH20 polypeptides are provided, including extended soluble PH20 polypeptides, and uses thereof. Also provided are other C-terminally truncated PH20 polypeptides and partially deglycosylated PH20 polypeptides and uses thereof.
    Type: Application
    Filed: February 21, 2012
    Publication date: April 25, 2013
    Inventors: Ge Wei, Krishnasamy Panneer Selvam, Louis Bookbinder, Gregory I. Frost
  • BTNL9 PROTEINS, NUCLEIC ACIDS, AND ANTIBODIES AND USES THEREOF
    Publication number: 20130101590
    Abstract: The invention provides novel BTNL9 proteins, including multimers, fragments, and variants of a human BTNL9 protein. In addition, antibodies that can bind to BTNL9 proteins and nucleic acids encoding BTNL9 proteins are provided. Uses for BTNL9 proteins, and agonists or antagonists thereof, are described.
    Type: Application
    Filed: April 8, 2011
    Publication date: April 25, 2013
    Inventors: Heather A. Arnett, Sabine S. Escobar, Ryan M. Swanson, Joanne L. Viney
  • NEUBLASTIN VARIANTS
    Publication number: 20130096065
    Abstract: Variant Neublastin polypeptides having substitutions at selected amino acid residues are disclosed. Substitution at one or more selected amino acid residues decreases heparin binding and increases serum exposure of variant Neublastin polypeptides. Also disclosed are methods of using variant Neublastin polypeptides to treat disorders and activate the RET receptor in a mammal.
    Type: Application
    Filed: July 3, 2012
    Publication date: April 18, 2013
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Anthony Rossomando, Laura Silvian, R. Blake Pepinsky
  • TRAIL R2-SPECIFIC MULTIMERIC SCAFFOLDS
    Publication number: 20130096058
    Abstract: The present invention provides Tenascin-3 FnIII domain-based multimeric scaffolds that specifically bind to TRAIL Receptor 2 (TRAIL R2), a cell membrane receptor involved in apoptosis. The invention further provides engineered variants with increased affinity for the target, increased stability, and reduced immunogenicity. Furthermore, the present invention is related to engineered multivalent scaffolds as prophylactic, diagnostic, or therapeutic agents, and their uses against diseases caused by cells expressing TRAIL R2, in particular to a therapeutic use against cancer.
    Type: Application
    Filed: April 12, 2011
    Publication date: April 18, 2013
    Applicant: MedImmune, LLC
    Inventors: Manuel Baca, Thomas Thisted, Jeffrey Swers, David Tice
  • BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF (S)-3-(1-AMINOETHYL)-PHENOL
    Publication number: 20130089898
    Abstract: The present disclosure provides engineered transaminase polypeptides having improved properties as compared to naturally occurring transaminases including the ability of converting the substrate, 3?-hydroxyacetophenone to (S)-3-(1-aminoethyl)-phenol in enantiomeric excess and high percentage conversion. Also provided are polynucleotides encoding the engineered transaminases, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases to synthesize (S)-3-(1-aminoethyl)-phenol and related compounds useful in the production of active pharmaceutical ingredients.
    Type: Application
    Filed: June 16, 2011
    Publication date: April 11, 2013
    Applicant: CODEXIS, INC.
    Inventors: Fabien Cabirol, Anupam Gohel, Seong Ho Oh, Derek Smith, Brian Wong, James Lalonde
  • BMP-2 Peptides and Methods of Use
    Publication number: 20130090290
    Abstract: The invention relates to truncated growth factors and variants thereof. The invention also relates to methods of making and using the truncated growth factors.
    Type: Application
    Filed: March 21, 2011
    Publication date: April 11, 2013
    Applicant: LIFENET HEALTH
    Inventors: Xiaofei Qin, Silvia Chen, Jingsong Chen, James A. Clagett
  • METHOD OF IMPROVING EFFICACY OF BIOLOGICAL RESPONSE-MODIFYING PROTEINS AND THE EXEMPLARY MUTEINS
    Publication number: 20130089513
    Abstract: Disclosed is a protein variant which substitutes valine for phenylalanine residue in a binding domain having a biological response-modifying function by binding to a receptor, ligand or substrate. Also, the present invention discloses a DNA encoding the protein variant, a recombinant expression vector to which the DNA is operably linked, a host cell transformed or transfected with the recombinant expression vector, and a method of preparing the protein variant comprising cultivating the host cell and isolating the protein variant from the resulting culture. Further, the present invention discloses a pharmaceutical composition comprising the protein variant and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: April 2, 2012
    Publication date: April 11, 2013
    Applicant: Medexgen Co., Ltd.
    Inventors: Yong-Hoon Chung, Hak-sup Lee, Ki-Wan Yi, Youn-Hwa Heo, Jae-Youn Kim
  • Circovirus sequences associated with piglet weight loss disease (PWD)
    Patent number: 8415525
    Abstract: The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.
    Type: Grant
    Filed: September 6, 2011
    Date of Patent: April 9, 2013
    Assignee: Zoetis W LLC
    Inventors: André Jestin, Emmanuel Albina, Pierre Le Cann, Philippe Blanchard, Evelyne Hutet, Claire Arnauld, Catherine Truong, Dominique Mahe, Roland Cariolet, François Madec
  • Cell Culture Compositions Capable of Producing a VEGF-Binding Fusion Polypeptide
    Publication number: 20130084635
    Abstract: The present invention provides cell culture compositions capable of producing fusion polypeptides that bind vascular endothelial growth factor (VEGF). The cell culture compositions of the invention comprise cells which contain an expression vector comprising a nucleic acid molecule encoding a fusion polypeptide that binds VEGF. The fusion polypeptides may comprise a VEGF receptor component having an immunoglobulin-like (Ig) domain 2 of a first VEGF receptor, an Ig domain 3 of a second VEGF receptor, and a multimerizing component.
    Type: Application
    Filed: November 21, 2012
    Publication date: April 4, 2013
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventor: Regeneron Pharmaceuticals, Inc.
  • TEAR LIPOCALIN IN MUTEINS BINDING IL-4 R ALPHA
    Publication number: 20130085113
    Abstract: The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha. The sequences of the muteins comprise particular combinations of amino acids. In particular a mutated amino acid residue is present at any one or more of the sequence positions 27, 28, 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104-106 and 108 of the linear polypeptide sequence of the mature human tear lipocalin. A mutated amino acid residue is also present at any 2 or more of the sequence positions 26, 32, 34, 55, 56, 58 and 63 of the linear polypeptide sequence of the mature human tear lipocalin. The invention also provides a corresponding nucleic acid molecule encoding such a mutein and a method for producing such a mutein and its encoding nucleic acid molecule.
    Type: Application
    Filed: June 8, 2011
    Publication date: April 4, 2013
    Inventors: Andreas Hohlbaum, Alexandra Baehre, Gabriele Matschiner, Stefan Trentmann, Klaus Kirchfeld, Hans-Juergen Christian
  • Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
    Patent number: 8409857
    Abstract: The present invention relates to a method for increased production of a secreted, recombinant protein product through the introduction of molecular chaperones in a mammalian host cell. The present invention also relates to a mammalian host cell with enhanced expression of a secreted recombinant protein product by coexpressing at least one chaperone protein.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: April 2, 2013
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Sham-Yuen Chan, Hsinyi Yvette Tang, Yiwen Tao, Yongjian Wu, Ruth Kelly
  • INCORPORATION OF TWO DIFFERENT NONCANONICAL AMINO ACIDS INTO A SINGLE PROTEIN
    Publication number: 20130078671
    Abstract: The invention relates to methods, systems, and compositions for the genetic incorporation of a plurality of different noncanonical amino acids into one target protein. The invention provides for multiple, mutually orthogonal aminoacyl-tRNA synthetase/tRNA pairs that suppress two different selector codons engineered into a polynucleotide molecule. By virtue of the suppression of the selector codons, orthogonal aminoacyl-tRNA synthetase/tRNA pairs permit incorporation of their charged noncanonical amino acids into the corresponding positions in the protein. The noncanonical amino acids provide a wide array of functional capabilities. For example, the noncanonical amino acids can provide a reactive pair of moieties that facilitate the study and manipulation of the target protein.
    Type: Application
    Filed: March 26, 2012
    Publication date: March 28, 2013
    Applicant: THE TEXAS A&M UNIVERSITY SYSTEM
    Inventor: Wenshe Liu
  • METHOD FOR OPTIMISING GENE EXPRESSION USING SYNONYMOUS CODON OPTIMISATION
    Publication number: 20130074218
    Abstract: The present invention discloses a method for modulating the quality of a selected phenotype that is displayed by an organism or part thereof and that results from the expression of a polypeptide-encoding polynucleotide by replacing at least one codon of that polynucleotide with a synonymous codon that has a higher or lower preference of usage by the organism or part thereof to produce the selected phenotype than the codon it replaces. The present invention is also directed to the use of a codon-modified polynucleotide so constructed for modulating the quality of a selected phenotype displayed by an organism or part thereof.
    Type: Application
    Filed: September 14, 2012
    Publication date: March 21, 2013
    Applicant: The University of Queensland
    Inventor: Ian Hector FRAZER